INCYTE CORP (INCY)

US45337C1027 - Common Stock

60.16  -0.17 (-0.28%)

News Image
3 hours ago - Chartmill

NASDAQ:INCY stands out as a growth opportunity that won't break the bank.

For those who appreciate growth without the sticker shock, INCYTE CORP (NASDAQ:INCY) is worth considering.

News Image
19 hours ago - InvestorPlace

Exit Now! 3 Biotech Stocks to Sell in February 2024

These biotech stocks to sell represent incredibly risky bets, amidst the sector's volatility and looming economic unpredictability.

News Image
8 days ago - Seeking Alpha

JMP cuts Incyte to market perform, cites need for acquisition (NASDAQ:INCY)

JMP has downgraded Incyte (INCY) to market perform, asserting that the company will likely need an acquisition to ensure its current cash flow. In its note, the

News Image
8 days ago - Chartmill

Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Wednesday.

Wednesday's session: top gainers and losers in the S&P500 index

News Image
10 days ago - Chartmill

Despite its impressive fundamentals, NASDAQ:INCY remains undervalued.

INCYTE CORP (NASDAQ:INCY) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.

News Image
13 days ago - Market News Video

Notable Friday Option Activity: AMGN, INCY, MU

News Image
15 days ago - Chartmill

What's going on in today's session: S&P500 movers

Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Wednesday.

News Image
15 days ago - FinancialNewsMedia

Pancreatic Cancer Treatments Poised for Major Advances in 2024

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:INCY),(NASDAQ:TNGX),(NASDAQ:RYZB),(NYSE:BMY) EQNX::TICKER_END

News Image
15 days ago - USA News Group

Pancreatic Cancer Treatments Poised for Major Advances in 2024

/PRNewswire/ -- USA News Group - One of the more worrying storylines of 2023 was the rising incidence of early-onset pancreatic cancer. As well, the deadly...

News Image
17 days ago - Investor's Business Daily

Biotech Stock MorphoSys Catapults 56% As Novartis Agrees To Buy It For $2.9 Billion

Novartis will add to its cancer treatment pipeline with via the German biotech.

News Image
17 days ago - Seeking Alpha

Incyte buys global rights for tafasitamab from MorphoSys (NASDAQ:INCY)

Incyte (INCY) has bought the global commercialization rights to tafasitamab, also known as Monjuvi, from partner MorphoSys (MOR) for $25M. Read more here.

News Image
17 days ago - Seeking Alpha

Novartis to buy cancer drugmaker MorphoSys AG for EUR 2.7B (NYSE:NVS)

Novartis strengthens its oncology pipeline with the acquisition of cancer drugmaker MorphoSys AG, expanding treatment options for patients.

News Image
17 days ago - Seeking Alpha

Novartis enters into agreement to buy cancer drugmaker MorphoSys AG for EUR 2.7B

Novartis strengthens its oncology pipeline with the acquisition of cancer drugmaker MorphoSys AG, expanding treatment options for patients.

News Image
17 days ago - InvestorPlace

Why Is MorphoSys (MOR) Stock Up 50% Today?

News of a potential takeout bid for any company usually leads to a big surge. That's what investors are seeing today with MOR stock.

News Image
17 days ago - Seeking Alpha

MorphoSys jumps amid report Novartis in takeover talks; Karyopharm surges in sympathy

Novartis is reportedly in advanced talks to acquire cancer drugmaker MorphoSys, potentially beating rival bidder Incyte, but no deal has been confirmed...

News Image
17 days ago - Bloomberg

MorphoSys Surges on Report Novartis Is in Talks to Buy Drugmaker

MorphoSys AG shares surged after a report that Novartis AG is in advanced talks to buy the German maker of cancer treatments.

News Image
17 days ago - Seeking Alpha

MorphoSys ADRs jump amid report Novartis in advanced talks to takeover

Novartis is reportedly in advanced talks to acquire cancer drugmaker MorphoSys, potentially beating rival bidder Incyte, but no deal has been confirmed...

News Image
22 days ago - Market News Video

Relative Strength Alert For Incyte

News Image
23 days ago - Seeking Alpha

Agilent, Incyte to collaborate on companion diagnostics development (NYSE:A)

Agilent Technologies and Incyte collaborate to develop advanced companion diagnostics in hematology and oncology, aiming for improved patient outcomes.

News Image
a month ago - InvestorPlace

3 Pharma Stocks Could Be the Pills Your Portfolio Needs

These large-cap pharma stocks offer growth and value with existing medicines, deep pipelines and reasonable valuations.

News Image
a month ago - Market News Video

Insulet Takes Over #420 Spot From Incyte

News Image
a month ago - Seeking Alpha

Aclaris stock downgraded at BTIG despite eczema trial win

BTIG downgraded Aclaris Therapeutics (ACRS) Thursday even after the company said its eczema therapy, ATI-1777, succeeded in a mid-stage trial. Find out the reasons.

News Image
2 months ago - Market News Video

Tuesday Sector Laggards: Services, Healthcare

News Image
2 months ago - InvestorPlace

AI Meets Biotech: 3 Top Stocks Transforming Medical Science

The AI revolution is bringing big gains to biotechnology, including drugs, antibodies, and synthetic biology.